• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Hydropyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Hydropyrimidines

Introduction to 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine (CAS No. 1691329-60-8)

6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by the CAS number 1691329-60-8, has garnered attention due to its potential applications in the development of novel therapeutic agents. The presence of a cyclopropyl group and a tetrahydropyrimidine core makes it a versatile scaffold for medicinal chemistry investigations.

The chemical structure of 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine consists of a six-membered heterocyclic ring system fused with an amine functional group. This configuration allows for diverse interactions with biological targets, making it a promising candidate for drug discovery. The cyclopropyl moiety enhances the compound's lipophilicity, which can be advantageous for membrane permeability and absorption profiles in vivo.

In recent years, there has been growing interest in tetrahydropyrimidine derivatives due to their broad spectrum of biological activities. These derivatives have been explored for their potential in treating various diseases, including cancer, infectious diseases, and neurological disorders. The amine group in 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine provides a site for further functionalization, enabling the synthesis of analogs with enhanced pharmacological properties.

One of the most compelling aspects of this compound is its role in the development of kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways and are often implicated in diseases such as cancer. By targeting specific kinases, inhibitors like those derived from 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine can modulate these pathways and potentially lead to therapeutic benefits. Recent studies have demonstrated the efficacy of related compounds in preclinical models, highlighting their promise as lead candidates for drug development.

The synthesis of 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Advanced synthetic methodologies have been employed to streamline the process and improve scalability. Techniques such as catalytic hydrogenation and nucleophilic substitution are commonly used in the construction of the tetrahydropyrimidine core. These methods ensure that the final product meets the stringent requirements for pharmaceutical applications.

The pharmacokinetic properties of 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine have been extensively studied to understand its behavior in biological systems. Metabolism studies indicate that the compound undergoes biotransformation via several pathways, including oxidative and reductive processes. These findings are crucial for predicting its half-life and potential side effects. Additionally, pharmacokinetic modeling helps in optimizing dosing regimens to maximize therapeutic efficacy while minimizing adverse effects.

From a regulatory perspective, 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine must comply with various guidelines set forth by global health authorities such as the FDA and EMA. These regulations ensure that the compound is safe and effective for human use. Compliance with Good Manufacturing Practices (GMP) is essential throughout its production process to maintain quality and consistency. Furthermore, preclinical and clinical trials are necessary to demonstrate its safety and efficacy before it can be approved for therapeutic use.

The future prospects of 6-Cyclopropyl-1,4,5,6-tetrahydropyrimidin-2-amine are promising as ongoing research continues to uncover new applications. Innovations in drug design and delivery systems may further enhance its potential as a therapeutic agent. Collaborative efforts between academia and industry are essential to accelerate the translation of laboratory findings into clinical practice. By leveraging cutting-edge technologies such as high-throughput screening and computational modeling， researchers can identify new derivatives with improved pharmacological profiles.

In conclusion， 6-Cyclopropyl-1，4，5，6-tetrahydropyrimidin-2-am ine represents a significant advancement in pharmaceutical chemistry with its unique structural features and broad range of potential applications。 Its role in developing kinase inhibitors， coupled with ongoing research efforts， positions it as a valuable compound in the quest for novel therapeutics。 As scientific understanding evolves， so too will the applications and benefits derived from this remarkable molecule。

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)